Citing AstraZeneca Plc's (NASDAQ:AZN) head of research and development, the Financial Times reported that the Company would consider not submitting its COVID-19 vaccine for approval in the U.S. if the regulatory process takes too long.
According to the report, AstraZeneca's R&D head, Mene Pangalos, said AstraZeneca would instead focus on selling the vaccine in other countries, though it will continue talks with the FDA. "We don't need to push it in places we are not needed or wanted," Pangalos told the Financial Times. If we don't end up submitting it for a BLA [biologics license application], I don't think it will have an impact around the world."
